<DOC>
	<DOCNO>NCT00566358</DOCNO>
	<brief_summary>Diabetes reversion observe bariatric surgery even significant weight loss could explain , mainly predominantly malabsorptive procedure ( 98,9 % biliopancreatic diversion duodenal switch ) , follow combine malabsorption gastric restriction ( 83,7 % Roux-en-Y gastric bypass ) . Changes hormonal communication digestive system pancreas would explain antidiabetogenic role surgery , effect could obtain nonobese , diabetic individual . In order try hypothesis , RUBINO MARESCAUX ( 2004 ) study gastrojejunal bypass ( duodenal exclusion ) mouse model diabetes without obesity . In technique stomach volume keep intact , maintain caloric ingestion weight animal . There fast improvement diabetes , independent diet weight , without potential nutritional deprivation commonly see bariatric surgery like iron vitamin deficiency . This study evaluate mechanism amelioration type 2 diabetes mellitus duodenal exclusion surgery human non-obese , diabetic volunteer know insulin secretion capacity , method standardize meal stimulus . It expect secondary change gastrointestinal hormone stimulate insulin secretion ( incretins ) . The knowledge clinical outcome technique human description secretion pattern gastrointestinal hormone surgery may contribute implementation surgery new therapeutic option overweight ( non-obese ) diabetic patient .</brief_summary>
	<brief_title>Surgical Treatment Non-obese Type 2 Diabetic Patients With Duodenal Exclusion</brief_title>
	<detailed_description>There large recovery insulin sensibility bariatric surgery , patient get close ideal weight . Diabetes reversion frequent predominantly malabsorptive procedure ( 98,9 % biliopancreatic diversion duodenal switch ) , follow combine malabsorption gastric restriction ( 83,7 % Roux-en-Y gastric bypass ) . Glycemia normalization occur early phase postoperative period , even significant weight loss could explain . These technique common bypass duodenum part jejunum . Many peptide release segment regulate pancreatic beta cell ( insulin producer ) either physiological state diabetes . Anatomical-functional change enteroinsular axis would explain antidiabetogenic role surgery , effect could obtain nonobese , diabetic individual . In order try hypothesis , RUBINO MARESCAUX ( 2004 ) study gastrojejunal bypass ( duodenal exclusion ) Goto-Kakizaki mouse ( GK ) , use animal model diabetes without obesity . In technique stomach volume keep intact , maintain caloric ingestion weight animal . There fast improvement diabetes , independent diet weight . The author conclude procedure apply human reversal diabetes without potential nutritional deprivation commonly see bariatric surgery like iron vitamin deficiency . The amelioration diabetes bariatric surgery related modulation production gastrointestinal hormone relevant insulin production ( incretin effect ) . This study evaluate mechanism amelioration type 2 diabetes mellitus duodenal exclusion surgery human non-obese , diabetic volunteer know insulin secretion capacity , method standardize meal stimulus . It expect secondary change gastrointestinal hormone stimulate insulin secretion ( incretins ) . The knowledge clinical outcome technique human description secretion pattern gastrointestinal hormone surgery may contribute implementation surgery new therapeutic option overweight ( non-obese ) diabetic patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<criteria>Age : 18 60 year . BMI 25 29,9 kg/mÂ² . Weight variance le 5 % last 3 month . Previous diagnosis diabetes type 2 . Insulin requirement , alone along oral agent Capacity understand procedure study . To agree voluntarily participate study , sign informed consent . Positive AntiGAD antibody Laboratorial signal probable failure insulin production , i. e. , seric peptide C lesser 1 ng/mL . History hepatic disease like cirrhosis chronic active hepatitis . Kidney dysfunction ( creatinine &gt; 1,4 mg/dl woman &gt; 1,5 mg/dl men ) . Hepatic dysfunction : ALT and/or AST 3x upper normal limit . Recent history neoplasia ( &lt; 5 year ) . Use oral injectable corticosteroid consecutive 14 day last three month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>diabetes mellitus , type 2</keyword>
	<keyword>duodenal exclusion</keyword>
	<keyword>bariatric surgery</keyword>
	<keyword>Glucagon-Like Peptide 1</keyword>
	<keyword>Gastric Inhibitory Polypeptide</keyword>
	<keyword>insulin</keyword>
	<keyword>glucagon</keyword>
	<keyword>ghrelin</keyword>
</DOC>